Related Experiment Videos
[p38 MAPK/cPLA2 pathway mediates interleukins release in inflammatory cell model]
Xiao-hui Wang1, Guang-tao Yan, Kai Zhang
1Research Laboratory of Biochemistry, Basic Medical Institute, General Hospital of PLA, Beijing 100853, China.
Objective:
To explore the underlying mechanism of lipopolysaccharide (LPS)-induced interleukin-1 beta (IL-1 beta) and IL-6 release via p38 mitogen-activated protein kinase (MAPK) pathway in HeLa cells for further identification of involved down-stream message factors.
Methods:
HeLa cells were challenged with LPS to reproduce inflammatory cell model. The activity or expression of p38 MAPK, cytosolic phospholipase A(2) (cPLA(2)) and COX-2, was inhibited with pretreatment of inflammatory HeLa cells with the inhibitors (SB203580, AACOCF(3), NS-398) or transfected with the cPLA(2) antisense oligonucleotide (SK7111), then the activities and/or expression of p38 MAPK, cPLA(2), COX-2, and relationship with levels of IL-1 beta and IL-6 supernatants were determined in each group.
Results:
SB203580 obviously down-regulated the activities of p38 and cPLA(2), as well as the release of IL-1 beta and IL-6. AACOCF(3) and SK7111 blocked dose-dependently the activity or expression of cPLA(2), IL-1 beta and IL-6 production. However, the expression of COX-2 could hardly be detected in HeLa cells, even after LPS treatment. At the same time, pre-treatment with NS-398 had no effect on IL-1 beta, IL-6 production.
Conclusion:
p38 MAPK/cPLA(2) pathway mediates the expression of IL-1 beta and IL-6 resulting from LPS treatment of HeLa cells, while COX-2, as a down-stream enzyme of cPLA(2) has no effect in this process.
Insights
Lipopolysaccharide (LPS) triggers interleukin-1 beta (IL-1 beta) and IL-6 release in HeLa cells via the p38 MAPK/cPLA(2) pathway. This study identifies p38 MAPK and cPLA(2) as key mediators, excluding COX-2
Area of Science:
- Cellular biology
- Immunology
- Molecular biology
Context:
- Lipopolysaccharide (LPS) is a potent activator of inflammatory responses.
- Interleukin-1 beta (IL-1 beta) and IL-6 are critical pro-inflammatory cytokines.
- HeLa cells are a widely used model for studying cellular responses to stimuli.
Purpose:
- To elucidate the mechanism of LPS-induced IL-1 beta and IL-6 release in HeLa cells.
- To investigate the role of the p38 mitogen-activated protein kinase (MAPK) pathway.
- To identify downstream signaling molecules involved in this inflammatory process.
Summary:
- LPS challenge in HeLa cells activated the p38 MAPK pathway.
- Inhibition of p38 MAPK and cytosolic phospholipase A(2) (cPLA(2)) significantly reduced IL-1 beta and IL-6 release.
- COX-2 expression was negligible and its inhibition did not affect cytokine production, indicating it is not involved.
Impact:
- Establishes the p38 MAPK/cPLA(2) signaling axis as central to LPS-induced IL-1 beta and IL-6 production in HeLa cells.
- Provides mechanistic insight into cytokine regulation.
- Offers potential targets for anti-inflammatory therapies.
Related Concept Videos
Acute Inflammation II: Cellular Phase
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
MAPK Signaling Cascades
Acute Inflammation I: Inflammatory Response
Inflammatory Response
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...